Skip to main content
Figure 2 | BMC Endocrine Disorders

Figure 2

From: Effects of human insulin and insulin aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes

Figure 2

IGF parameters profiles. (a) Serum total IGF-I concentration, (b) bioactive IGF concentration, (c) IGFBP-1 concentration, *P < 0.01 as BIAsp50 compared with insulin aspart and human insulin for AUC0–3; **P < 0.05, as BIAsp50 compared with human insulin for AUC3–6; ***P < 0.05, as BIAsp70 compared with human insulin for AUC0–9. (d) IGFBP-2 levels and (e) IGFBP-3 levels during 9-hour treatment with insulin aspart (open circles), BIAsp70 (black rectangles), BIAsp50 (open rectangles) and human insulin (black circles). For clarity, serum concentrations are illustrated as mean levels only.

Back to article page